Veerhealth care Limited has announced securing a substantial international order worth $1,60,650 (approximately ₹150 lakhs) from a New York-based company for personal care products. The announcement was made on April 11, 2026, through a regulatory filing under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Order Details and Financial Impact

The order represents a significant business opportunity for the company, with management anticipating additional growth in turnover from this international engagement. The contract involves the supply of body care products to be executed within a 45-day timeframe.

Regulatory Compliance and Disclosure

The company has provided comprehensive details as required under SEBI regulations, ensuring full transparency regarding the transaction. Key regulatory aspects include:

• Client Identity: Not disclosed due to confidential terms
• Transaction Nature: International supply contract
• Related Party Status: No related party involvement
• Promoter Interest: No promoter or group company interest in the awarding entity

Business Significance

This international order demonstrates Veerhealth Care's expanding presence in global markets, particularly in the personal care segment. The contract's execution within 45 days indicates the company's operational readiness to fulfill international demands efficiently.

The order falls under the company's body care products portfolio, highlighting the market acceptance of their ayuVeer brand in international markets. With manufacturing facilities located at Vapi, Gujarat, the company is well-positioned to execute this order within the specified timeframe.

Company Operations

Veerhealth Care Limited operates with its registered office in Mumbai and manufacturing works at Plot No. 224, Vibrant Business Park, Vapi, Gujarat. The company's dual-brand strategy includes both Veerhealth Care and ayuVeer product lines, catering to domestic and international markets.

Veerhealth Care Limited has submitted newspaper publication documents to BSE Limited regarding the postal ballot notice for preferential warrant issuance, following the board approval granted on March 28, 2026. The company filed the regulatory compliance documentation under Regulation 47 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

BSE Submission and Regulatory Compliance

The company submitted official documentation to BSE on April 01, 2026, confirming newspaper publication of the postal ballot notice extract. Managing Director Bhavin S. Shah (DIN: 03129574) signed the submission letter, ensuring compliance with mandatory disclosure requirements.

E-Voting Schedule and Process

The postal ballot notice establishes a comprehensive e-voting framework for shareholder approval of the preferential warrant allotment. The cut-off date for determining eligible shareholders has been set as March 27, 2026, with voting rights proportional to shareholding as of this date.

Warrant Issue Structure and Allocation

The preferential issue comprises up to 1,00,00,000 fully convertible warrants at Rs 20.25 per warrant, totaling Rs 20.25 crores. The warrants provide rights to subscribe to equivalent equity shares of face value Rs 10 each within 18 months from allotment.

Fund Utilization and Corporate Objectives

The company has outlined specific deployment strategies for the Rs 20.25 crores proceeds, focusing on manufacturing capacity expansion and operational enhancement. The funds will support plant and machinery acquisition, electrical and electronics installation, furniture and fixtures, office equipment including computers and software, and general corporate purposes.

Regulatory Compliance and Pricing Framework

The warrant issue price of Rs 20.25 per warrant has been determined in accordance with Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The relevant date for minimum price computation is March 31, 2026, with the issue price exceeding both the market-based minimum of Rs 20.10 and the independent valuation report threshold.

Proposed allottees must pay at least 25% of the warrant issue price before allotment, with the remaining 75% payable upon exercising conversion rights. The warrants and resulting equity shares will be subject to lock-in provisions as per SEBI ICDR Regulations, with allotment to be completed within 15 days of shareholder approval.